Illumina, Inc., a global leader in genomics and precision health, has announced the launch of BioInsight, a new business designed to meet the growing demand for deeper biological insights driven by large-scale multiomic data. By combining Illumina’s expertise in sequencing, data analysis, software and artificial intelligence, BioInsight will support researchers and pharmaceutical companies in identifying drug targets, understanding disease mechanisms, and accelerating therapeutic development. The initiative highlights Illumina’s commitment to advancing science, health care, and sustainable growth through cutting-edge innovation.

BioInsight will be led by Rami Mehio, appointed senior vice president and general manager, who previously headed Illumina’s Global Software & Informatics team. Commenting on the launch, Illumina’s chief executive officer Jacob Thaysen said that BioInsight will strengthen the company’s leadership at the intersection of sequencing, AI and software, while enabling transformative drug discovery and development. Mehio added that the convergence of affordable large-scale sequencing and advanced AI is revolutionising how scientists derive biological insights, and Illumina is committed to partnering with stakeholders to turn these massive datasets into meaningful discoveries.

The new business will focus on several key areas, including working with national research initiatives and industry partners to generate large-scale genetic and biological data, developing software solutions to analyse multimodal data at a population level, providing secure platforms for data access, and advancing AI-driven tools through strategic partnerships. These efforts will extend beyond genomics to encompass multiomic and advanced biological data types such as perturb-seq, further broadening the scope of insights available to customers.

Illumina emphasises that progress in life sciences is accelerating as researchers increasingly rely on AI and software to interpret vast, complex datasets. BioInsight aims to facilitate multimodal data aggregation and federated data networks, empowering scientists to identify patterns, discover novel targets, and improve disease diagnosis and treatment with greater speed and accuracy. By enabling scalable data generation and AI solutions, Illumina positions BioInsight as a pivotal driver of transformative research, bridging the gap between omics data creation and actionable biological insights.

Through this new venture, Illumina reinforces its role as a pioneer in genomics and human health, leveraging its technological strengths to help shape the next generation of drug discovery and precision medicine.